CLOs on the Move


 
KCR is a clinical development solutions provider for the biotechnology, pharmaceutical, and medical device industries. We support clients with full-service clinical development capabilities across three main areas: Trial Execution, Consulting and Placement. KCR operates across four main regions: North America, Western Europe, Central Europe, and Eastern Europe, with a main operational hub located in Boston, MA. Our strategic hub locations, technical capabilities and solution offerings allow for the optimized delivery of trial execution strategies to develop life-changing therapies. KCR offers access to an estimated population of 1.1 Billion people.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.kcrcro.com
  • 30 Rowes Wharf Suite 430
    Boston, MA USA 10117
  • Phone: +48 22 313 13 13

Executives

Name Title Contact Details

Similar Companies

Medico Labs Inc

Medico Labs Inc is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NightstaRx

Nightstar is a private biopharmaceutical company focused on the development of therapies for retinal dystrophies. The Company’s lead programme is a retinal gene therapy for choroideremia, a rare inherited cause of blindness that affects around 1 in 50,000 people. Gene therapy has the potential to be an effective treatment for choroideremia and a range of other retinal dystrophies. The Company’s lead investors are Syncona LLP and NEA Inc. Syncona is an evergreen investment company, taking an active role in identifying, supporting and developing technologies with the potential to impact significantly the healthcare market of the future. NEA is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies.

fusionmed

fusionmed is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Perimeter Medical Imaging AI

Perimeter Medical Imaging is a medical device company driven to transform cancer surgery with advanced OCT technology for surgeons as they strive for clean margins to avoid re-excisions.

Phathom Pharmaceuticals

Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.